Spatiotemporal release of BMP-2 and VEGF enhances osteogenic and vasculogenic differentiation of human mesenchymal stem cells and endothelial colony-forming cells co-encapsulated in a patterned hydrogel

Danial Barati,¹ Seyed Ramin Pajoum Shariati,¹ Seyed sina Moeinzadeh,¹ Juan M. Melero-Martin,²

Ali Khademhosseini,^{3,4,5,6} Esmail Jabbari¹

¹*Biomimetic Materials and Tissue Engineering Laboratory, Department of Chemical Engineering, University of South Carolina, Columbia, SC 29208, USA*

²*Department of Cardiac Surgery, Boston Children's Hospital, Boston, MA, 02115, USA*

³*Biomaterials Innovation Research Center, Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston 02139, MA, USA*

⁴*Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge 02139, MA, USA*

⁵*Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston 02115, MA, USA*

⁶*Department of Bioindustrial Technologies, College of Animal Bioscience and Technology, Konkuk University, Hwayangdong, Gwangjin-gu, Seoul 143-701, Republic of Korea*

Submitted to Journal of Controlled Release

Word count not including references: 7823

Word count with references: 9723

Corresponding author:

Esmail Jabbari, Ph.D.

Associate Professor of Chemical and Biomedical Engineering

Swearingen Engineering Center, Rm 2C11

University of South Carolina

Columbia, SC 29208

Tel: (803) 777-8022

Fax: (803) 777-0973

Email: jabbari@mailbox.sc.edu

ABSTRACT

Reconstruction of large bone defects is limited by insufficient vascularization and slow bone regeneration. The objective of this work was to investigate the effect of spatial and temporal release of *recombinant human* bone morphogenetic protein-2 (BMP2) and vascular endothelial growth factor (VEGF) on the extent of osteogenic and vasculogenic differentiation of human mesenchymal stem cells (hMSCs) and endothelial colony-forming cells (ECFCs) encapsulated in a patterned hydrogel. Nanogels (NGs) based on polyethylene glycol (PEG) macromers chain-extended with short lactide (L) and glycolide (G) segments were used for grafting and timed-release of BMP2 and VEGF. NGs with 12 kDa PEG molecular weight (MW), 24 LG segment length, and 60/40 L/G ratio (P12-II, NG(10)) released the grafted VEGF in 10 days. NGs with 8 kDa PEG MW, 26 LG segment length, and 60/40 L/G ratio (P8-I, NG(21)) released the grafted BMP2 in 21 days. hMSCs and NG-BMP2 were encapsulated in a patterned matrix based on acrylate-functionalized lactide-chain-extended star polyethylene glycol (SPELA) hydrogel and microchannel patterns filled with a suspension of hMSCs+ECFCs and NG-VEGF in a crosslinked gelatin methacryloyl (GelMA) hydrogel. Groups included patterned constructs without BMP2/VEGF (None), with directly added BMP2/VEGF, and NG-BMP2/NG-VEGF. Based on the results, timed-release of VEGF in the microchannels in 10 days from NG(10) and BMP2 in the matrix in 21 days from NG(21) resulted in highest extent of osteogenic and vasculogenic differentiation of the encapsulated hMSCs and ECFCs compared to direct addition of VEGF and BMP2. Further, timed-release of VEGF from NG(10) in hMSC+ECFC encapsulating microchannels and BMP2 from NG(21) in hMSC encapsulating matrix sharply increased bFGF expression in the patterned constructs. The results suggest that mineralization and vascularization are coupled by localized secretion of paracrine signaling factors by the differentiating hMSCs and ECFCs.

KEY WORDS: nanogel grafting; *rh*BMP-2; VEGF; dual protein delivery; patterned hydrogel; human MSC; ECFC; osteogenesis; vasculogenesis.

1. Introduction

The reconstruction of large bone defects with implanted scaffolds due to resection of tumors, skeletal trauma, or infection remains a significant clinical problem [1]. The high clinical failure rates with allografts and implanted scaffolds are attributed to insufficient vascularization and slow bone regeneration [2]. Engineered matrices that can guide concerted differentiation of multiple cell types to both vasculogenic and osteogenic lineages are very promising for the treatment of skeletal injuries. In that regard, natural and synthetic matrices loaded with bone morphogenetic proteins (BMPs), with or without mesenchymal stem cells (MSCs), have been used extensively as a graft to accelerate bone healing [3]. Among BMPs, *recombinant human* BMP-2 (hereafter referred to as BMP2) is used as a potent osteogenic factor in certain clinical applications including spine fusion and alveolar ridge augmentation [4]. Similarly, the widely used vascular endothelial growth factor (VEGF) is not only involved in angiogenesis, but it is also implicated in maturation of osteoblasts, ossification, and bone turnover [5,6]. As the bioactivity of BMP2 and VEGF is concentration and time-dependent [7-9], their sustained delivery from biodegradable matrices has been investigated [10-14].

Osteogenesis and vascularization are coupled during bone development and growth [5,15]. VEGF plays a central role in blood vessel invasion into hypertrophic cartilage as the endothelial cells in the invading vessels secrete growth factors that stimulate osteogenesis [5,16]. There is a close correlation between vascularization and bone formation in endochondral ossification as the maximum extent of bone formation follows maximum levels of VEGF expression [17]. In the bone marrow, endothelial progenitor cells (EPCs) form an osteoblast-vascular niche by close proximity to osteoprogenitor cells in the endosteum [18]. Hence, several studies have investigated the combined effect of BMP2 and VEGF on differentiation of MSCs and EPCs [19-25]. Co-transfection of BMP2 and VEGF in MSCs [19], combination of BMP2-transfected MSCs and endothelial progenitor cells (EPCs) in porous calcium sulfate scaffolds [20], and timed-release or localized delivery of BMP2 and VEGF in porous scaffolds [22,24,25] have been used to investigate the effect of dual delivery of VEGF and BMP2 on osteogenesis and vascularization *in*

vitro and the extent of bone formation *in vivo*. The previous studies suggest that osteogenesis and vascularization may be dependent on timed and localized action of BMP2 on MSCs and VEGF on EPCs [26]. We hypothesized that osteogenesis and vascularization are coupled by spatiotemporal regulation of paracrine signaling in which the invading endothelial cells secrete osteogenic morphogens to stimulate MSC differentiation and bone formation. In this work, the hypothesis was tested *in vitro* with human MSCs (hMSCs) and human colony-forming endothelial cells (ECFCs) encapsulated in a patterned hydrogel with spatiotemporal release of BMP2 and VEGF.

PLGA micro- and nanoparticles (NPs) due to their wide range of degradation times are used for immobilization and timed-release of BMP2 and VEGF [10,13,27,28]. However, protein denaturation by surface adsorption and acidic degradation products of PLGA can significantly reduce bioactivity [29,30]. Due to the hydrophilicity and chain flexibility of polyethylene glycol (PEG), PEGylation is used to increase stability of PLGA NPs in aqueous suspensions, enhance protein stability, and reduce particle phagocytosis [10,13,31,32]. Protein encapsulation in self-assembled peptide nanofiber hydrogel scaffolds is used for timed-release of functional proteins but the release is dependent on protein size and fiber density [33]. Tethering to a peptide nanofiber hydrogel matrix by biotin-streptavidin complexation was utilized for protein immobilization and to increase protein's residence time in the matrix but protein-peptide interactions affected the extent of protein interaction with the embedded cells [34]. We have previously shown that PEG macromers chain-extended with short L/G segments form micellar structures in aqueous solution [35]. In this work, PEG macromers chain-extended with short lactide (L) and glycolide (G) segments were used to form nanogels (NGs) for grafting and timed-release of BMP2 and VEGF proteins. In the chain-extended macromer, the PEG block imparts stability to NGs in aqueous solution, L segment leads to self-assembly and NG formation, and G segment controls NG degradation and protein release. The release kinetics of proteins from PEG-based nanogels is dependent on length of the degradable segment but independent of protein size. Further, the protein is in the aqueous and inert PEG environment

which reduces protein denaturation. To generate a patterned hydrogel, microchannels were formed in a lactide-chain-extended star polyethylene glycol (SPELA) hydrogel. hMSCs and BMP2-grafted NGs (NG-BMP2) were encapsulated in the SPELA hydrogel and the microchannels were injected with a suspension of ECFCs+hMSCs and VEGF-grafted NGs (NG-VEGF) in gelatin methacryloyl (GelMA) hydrogel and crosslinked. The patterned constructs were cultured in vasculogenic/osteogenic medium (without VEGF or BMP2) and characterized with respect to the extent of osteogenic/vasculogenic differentiation of hMSCs and ECFCs. Although NGs based on PEG macromers chain-extended with short L/G segments is a unique platform for tunable release of growth factors such as BMP2 and VEGF, the most novel aspect of this work is mimicking the osteoblast-vascular niche during bone development and the fundamental understanding of the effect of spatiotemporal release of BMP2 and VEGF in a patterned construct on localized secretion of paracrine signaling factors by the differentiating hMSCs and hMSCs+ECFCs in the matrix and channels, respectively.

2. Material and Methods

2.1. Materials

Lactide (L) and glycolide (G) monomers with >99.5% purity (Ortec, Easley, SC) were dried under vacuum at 40°C for at least 12 h before use. Poly(ethylene glycol) (PEG, Mw=4, 8 and 12 kDa), porcine skin gelatin (type A, 300 bloom), human VEGF, *rh*BMP-2, their Enzyme-Linked Immunosorbent Assay (ELISA) kits, deuterated chloroform, tin (II) 2-ethylhexanoate (TOC), dimethylsulfoxide (DMSO), methacrylic anhydride (MA), Alizarin red, and 4,6-diamidino-2-phenylindole (DAPI) were received from Sigma-Aldrich (St. Louis, MO). Dichloromethane (DCM, Acros Organics, Pittsburg, PA) was dried by distillation over calcium hydride. Diethyl ether, dimethylformamide (DMF) and hexane were received from VWR (Bristol, CT). Dialysis tubing with 3.5 kDa cutoff MW was received from Spectrum Laboratories (Rancho Dominguez, CA). N,N'-disuccinimidyl carbonate (DSC) and bovine serum albumin (BSA) were received from Novabiochem (EMD Biosciences, San Diego, CA) and Jackson ImmunoResearch (West Grove, PA), respectively. EBM-2 medium, human basic fibroblast growth factor (bFGF), R³-

insulin like growth factor-1 (IGF-1), human epidermal growth factor (EGF), ascorbic acid (AA), β -sodium glycerophosphate (β GP), dexamethasone (DEX), hydrocortisone, gentamycin sulfate (GS), penicillin (PN), streptomycin (SP), and amphotericin-B were received from Lonza (Hopkinton, MA). PECAM-1 (CD31) and bovine anti-rabbit IgG-FITC (secondary antibody) were received from Santa Cruz Biotechnology (Dallas, TX). bFGF (FGF2) ELISA kit was received from MyBioSource (San Diego, CA).

2.2. Macromer synthesis for cell encapsulation in the hydrogels

SPELA macromer with 5 kDa PEG MW and L:PEG molar ratio of 6.3 was synthesized as we previously described [36]. Acrylamide-terminated glycine-arginine-glycine-aspartic acid (Ac-GRGD) peptide was synthesized in the solid phase and purified as we previously described [37]. GelMA was synthesized by the reaction of gelatin with MA as described [38]. Briefly, MA with a molar ratio of 100:1 (MA:gelatin) was added to a solution of gelatin (10% w/v) in PBS at 50°C under rigorous stirring. After running the reaction for 1 h, the mixture was 5X diluted with warm PBS and dialyzed against deionized (DI) water at 40°C for 3 days. The solution was lyophilized to obtain a white foam and stored at -20°C.

2.3. Synthesis and functionalization of PEG-LG block copolymer

The PEG-LG block copolymer was synthesized by melt ring-opening polymerization with successive addition of L and G monomers to the reaction using PEG as the initiator and TOC as the catalyst. PEG and lactide were added to a reaction flask equipped with a stirrer and immersed in an oil bath in a molar ratio based on the desired L segment length (Table 1). Next, the flask was heated to 120°C under nitrogen flow and maintained at that temperature for 1 h to remove residual moisture. Then, TOC catalyst was added to the mixture at 120°C and the reaction was allowed to proceed for 6 h at 140°C. The lactide chain-extended PEG macromer was used as initiator for chain extension with G monomer with a predetermined L to G ratio (Table 1). The reaction was allowed to proceed for 6 h at 140°C and the product was precipitated in ice-cold hexane to remove the unreacted monomers. The synthesized copolymer was functionalized with succinimide groups by reaction with DSC as we described previously

[39]. The product was purified by dialysis against DI water and lyophilized. The chemical structure of the synthesized copolymer was characterized by a Varian Mercury-300 ^1H -NMR (Varian, Palo Alto, CA) as we previously described [40]. The synthesized macromers are hereafter referred to as PaLGb-Lc (Tables 1 and 2) where the lowercase letter “a” is PEG MW in kDa, “b” is LG to PEG molar ratio, and “c” is the mole fraction of lactide in LG segments. The shorter abbreviations P4-I,II,III, P8-I,II,III, and P12-I,II,III stand for those macromers based on 4, 8, and 12 kDa PEG MW, respectively.

2.4. Nanogel formation and protein grafting

PaLGb-Lc macromer was dissolved in DMSO and self-assembled to form NGs by dialysis (3.5 kDa MW cutoff) against PBS for 8 h as we previously described (Figure 1a) [10]. For BMP2 or VEGF grafting, 10 mg NGs was suspended in 0.5 mL PBS by sonication for 1 min. Next, 0.5 mL of the protein in PBS (20 mg/mL for BSA, 800 ng/mL for BMP2 and VEGF) was added to the NG suspension. The amine group of the protein was allowed to react with succinimide end-groups of PaLGb-Lc in NGs under ambient conditions for 12 h as we previously described (Figure 1a) [27]. To determine grafting efficiency, the protein grafted NGs were resuspended in PBS and centrifuged at 18,000 rcf for 10 min and the supernatant was analyzed for total protein content by the ninhydrin reagent for BSA and ELISA for BMP2/VEGF as we described previously [10,37]. Grafting efficiency was determined by dividing the amount of attached protein (total - free protein) by the initial amount in the grafting reaction.

Figure 1. (a) Schematic diagram for NG assembly and protein grafting. The diagram is for illustration of protein grafting and is not intended to show the actual nanostructure of the NGs. (b) Schematic diagram for vasculogenic GelMA microchannels in osteogenic SPELA gel for patterned constructs. The SPELA precursor solution loaded with hMSCs and NG-BMP2 was

injected inside a Teflon cylinder (5 mm diameter and 3 mm height) fitted with 12 needles spaced 500 μm apart. After gelation, the needles were removed and the GelMA precursor solution, loaded with ECFCs+hMSCs (50:50) and NG-VEGF, was injected in the microchannels and UV crosslinked. Next, the cell-encapsulated construct was incubated in vasculogenic medium (without VEGF) for the first week, 50:50 mixture of vasculogenic and osteogenic medium (without VEGF, BMP2, or DEX) for three days (days 8-10), and finally in osteogenic medium for days 11-21 (without DEX or BMP2).

Size distribution of the NGs was measured by dynamic light scattering with a Submicron Particle Sizer (Model 370, NICOMP, Santa Barbara, CA) as we described previously [27]. Polydispersity (PD) of the NGs was determined using the equation $PD = \Delta d / \langle d \rangle$ where Δd and $\langle d \rangle$ are the standard deviation and mean size of the NGs, respectively. Zeta potential of the NGs was measured with a ZetaPlus analyzer (Brookhaven Instruments, Holtsville, NY) with a particle concentration of 2.5 mg/mL at 25°C in PBS. NGs degradation kinetics was measured by incubation in PBS at 37°C as we described previously [10]. The fractional mass remaining was determined by dividing the dried mass at time t by the initial mass. For measurement of release kinetics, 1 mg protein grafted NGs were incubated in 1 mL PBS at 37°C as we previously described [10]. At each time point, the suspension was centrifuged at 18350 rcf for 10 min, the supernatant was removed, the NGs were resuspended in 1 mL fresh PBS and incubated until the next time point. The amount of BSA in the supernatant was measured with the ninhydrin reagent as described [37]. In the case of BMP2 and VEGF-grafted NGs, the protein concentration in the supernatant was measured by ELISA as we described previously [10]. The phrase “bioactive protein” used hereafter for BMP2 and VEGF refers to the amount of protein measured by ELISA.

Table 1. Number average molecular weight $\overline{M}_n$, LG to PEG feed ratio, average number of L and G segments per macromer in PaLGb-Lc.

Group	Macromer type	$\overline{M}_n (\pm 100)$	LG/PEG(L/G) feed molar ratio	L/end group (± 0.1)	G/end group (± 0.1)
P4-I	P ₄ LG8-L75	5100	12 (75/25)	3.1	0.9
P4-II	P ₄ LG8-L60	5100	12 (60/40)	2.5	1.5
P4-III	P ₄ LG8-L50	5200	12 (50/50)	2.2	2.1
P8-I	P ₈ LG16-L75	10300	20 (75/25)	6.4	2.0
P8-II	P ₈ LG16-L60	10100	20 (60/40)	4.6	3.1
P8-III	P ₈ LG16-L50	10000	20 (50/50)	3.8	4.0
P12-I	P ₁₂ LG24-L75	15200	30 (75/25)	8.9	2.6
P12-II	P ₁₂ LG24-L60	15000	30 (60/40)	6.7	4.4
P12-III	P ₁₂ LG24-L50	14900	30 (50/50)	5.3	5.7

2.5. Cell culture

hMSCs (Lonza, Allendale, NJ) were cultured in a high glucose DMEM medium supplemented with 10% FBS, 100 units/mL penicillin and 100 µg/mL streptomycin (basal medium) at a seeding density of 5000 cells/mL as described [41]. After reaching 70% confluency, hMSCs were enzymatically lifted with trypsin-EDTA and used for cell encapsulation. All hMSCs were passaged <5 times prior to cell encapsulation according to supplier's instructions. Human ECFCs (Boston Children Hospital) were cultured in full EGM-2 medium (BulletKit, Lonza) supplemented with 20% FBS on 1% gelatin-coated flasks at a density of 6500 cells/mL as described [42]. Cobblestone-like cell colonies were detected after a week of cultivation and expanded by enzymatic lifting with 0.1% trypsin- 0.03% EDTA. All ECFCs were passaged <4 times prior to cell encapsulation according to established protocols [42].

2.6. Encapsulation of hMSCs and ECFCs in the unpatterned constructs

For unpatterned osteogenic constructs, hMSCs and NG-BMP2 were encapsulated in SPELA hydrogel and cultured in osteogenic medium without DEX or BMP2 (basal medium plus 50 µg/mL AA and 10 mM βGP). Osteogenic constructs included hMSCs in SPELA gel without BMP2, with directly added BMP2, and NG-BMP2. Briefly, 20 mg of NG-BMP2 (1.2 µg BMP2) were suspended in 1 mL of SPELA gel precursor solution [200 mg SEPLA macromer, 4 mg Ac-GRGD (2 wt% of macromer for cell adhesion) and 7.5 mg (0.75 wt%) photo-initiator (Irgacure-2959, CIBA)] and the suspension was sterilized by filtration. Next, hMSCs at a density of 2×10^6 cells/mL were suspended in the sterile SPELA precursor solution, injected between two sterile glass slides, and crosslinked by UV irradiation as we previously described [43]. For the unpatterned vasculogenic constructs, a 50:50 mixture of hMSCs+ECFCs [43] plus NG-VEGF was encapsulated in GelMA hydrogel and cultured in EMB-2 BulletKit medium without the addition of VEGF. Vasculogenic constructs included hMSCs+ECFCs in GelMA hydrogel without VEGF, with directly added VEGF, and NG-VEGF. Briefly, 2 mg NG-VEGF (120 ng VEGF) was suspended in 1 mL of GelMA precursor solution (50 mg GelMA and 7.5 mg photo-initiator) and sterilized. Next, 50:50 mixture of hMSCs+ECFCs at a total density of 2×10^6

cells/mL was suspended in the sterile GelMA precursor solution, injected between glass slides, and crosslinked by UV irradiation as described [43]. After gelation, disk-shape gels (7 mm diameter and 0.5 mm thickness) were cut and incubated in PBS for 1 h with two PBS changes. Next, the media was replaced with osteogenic (without DEX or BMP2) or vasculogenic (without VEGF) medium and incubated for 21 and 10 days, respectively.

2.7. Encapsulation of hMSCs and ECFCs in the patterned constructs

Patterned hydrogels with GelMA micro-channels in a SPELA matrix were generated for osteogenic-vasculogenic co-culture experiments. Twelve 400- μ m diameter needles (G-20) were inserted through the end-caps of a Teflon cylinder with diameter and height of 5 and 3 mm, respectively. The distance between the needles was 500 μ m. Next, the sterile SPELA precursor solution (20 mg NG-BMP2 and 2×10^6 hMSCs in 1 mL PBS) was injected between the needles and crosslinked with UV as described (Figure 1b) [43]. Then, the needles were removed and the GelMA precursor solution (2 mg NG-VEGF and 2×10^6 hMSCs/ECFCs in 1 mL PBS) was injected in the channels and crosslinked with UV as described (Figure 1b) [43]. After gelation, the patterned constructs were washed with PBS and incubated in vasculogenic medium (without VEGF) for the first week, 50:50 mixture of vasculogenic and osteogenic medium (without VEGF, BMP2, or DEX) for the next three days (days 8-10), and finally in osteogenic medium (without DEX or BMP2) for 11 days (days 11-21). Experimental groups included patterned constructs without BMP2/VEGF, BMP2 directly added to SPELA gel plus VEGF to GelMA, and NG-BMP2 in SPELA gel plus NG-VEGF in GelMA.

2.8. Biochemical, mRNA, and protein analysis

At each time point, the constructs were washed with serum-free DMEM for 8 h to remove serum proteins, washed with PBS, and sonicated to rupture the membrane of the encapsulated cells [41]. Next, the samples were divided into three groups for biochemical, mRNA, and protein analysis. The first group of samples were homogenized in 10 mM Tris supplemented with 0.2% triton lysis buffer and used for the measurement of double-stranded DNA content (in ng/mL gel) with PicoGreen (Quant-it, Invitrogen), alkaline phosphates (ALP) and calcium

(QuantiChrom, BioAssay Systems) assays, respectively, as we previously described [41]. The samples in the second group were homogenized in TRIzol (Invitrogen) lysis buffer to extract total cellular RNA and the extracted RNA was subjected to cDNA synthesis and rt-qPCR amplification for the expression of osteogenic genes [RUNX2, Collagen type I (Col I) and ALP] and vasculogenic genes (CD31, VE-cadherin and vWF) as we previously described [41]. The forward and reverse primers shown in Supplementary Table S1 were designed using the Primer3 web-based software as described [44] and synthesized by Integrated DNA technologies (Coralville, IA). The designed primer sequences were consistent with the previously reported sequences for RUNX2, Col I, ALP, CD31, VE-cadherin, and vWF [45-49]. The mRNA fold difference in expression for the gene of interest in each experimental group at any time point was calculated by first normalizing the gene expression to that of GAPDH house-keeping gene followed by normalization against day one expression for that gene as described [41] to compare expressions between the groups.

The samples in the third group were homogenized in radioimmunoprecipitation RIPA lysis buffer with Protease Inhibitor Cocktail (Life Technologies) to extract the proteins according to manufacturer's instructions. Next, the proteins were separated by standard SDS-PAGE using the Mini-gel system (Bio-Rad) and transferred to a nitrocellulose membrane by the semi-dry transfer apparatus (Bio-Rad). Membranes were incubated in the blocking buffer at ambient conditions for 1 h followed by incubation with primary antibodies (1:1000) overnight at 4°C. After washing, the membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (1:5000) for 1 h at ambient conditions. After extensive washing with a mixture of tris-buffered saline and Tween-20, the membrane was incubated with enhanced luminol-based (ECL) detection reagents and the luminescence was captured using a Biorad ChemiDoc MP system. The intensity of the bands was quantified with Image-J software (National Institutes of Health, Bethesda, MD).

2.9. Alizarin red and Immunofluorescent staining

The samples were fixed with 4% paraformaldehyde. To stain for mineralization, the fixed samples were covered with a solution of Alizarin red, according to the manufacturer's instructions, and incubated in the dark at ambient conditions for 10 min. For CD31 staining, the fixed samples were permeabilized in PBS with 0.1% Triton X-100 and 100 mM glycine for 1 h and blocked in PBS with 1% BSA and 10% FBS for 1 h. Next, samples were incubated with the primary antibody (1:100 dilution) in PBS containing 1% BSA at 25°C for 1 h. After washing with PBS, samples were incubated in the blocking solution for 1 h followed by incubation in the secondary antibody solution (bovine anti-rabbit IgG-FITC, 1:100 dilution) at ambient conditions in the dark for 1 h. Then, samples were counterstained with DAPI to image the cell nuclei. Secondary antibodies without the primaries were used as negative controls. Stained samples were imaged with a Nikon Eclipse Ti-ε inverted fluorescent microscope.

2.10. Statistical analysis

Data are expressed as means $\pm$ standard deviation. All experiments were done in triplicate. Significant differences between groups were evaluated using a two-way ANOVA with replication test, followed by a two-tailed Students t-test. A value of $p < 0.05$ was considered statistically significant.

3. Results

3.1. Macromer characterization

The average number of L/G units per PaLGb-Lc was calculated from ^1H -NMR spectra of the macromer (representative spectra in Supplementary Figure S1). Two chemical shifts with peak positions at 1.6 and 5.2 ppm, two at 3.6 and 4.2 ppm and one at 4.8 ppm were attributed to the methyl and methine hydrogens of lactide, the methylene hydrogens of PEG and the methylene hydrogens of glycolide, respectively [39,43]. The chemical shift with peak position at 2.77 ppm was related to the methylene hydrogens of succinimide end-groups. The average segment length of L and G units per macromer and the number-average MW ($\overline{M}_n$) of the macromers are shown in Table 1. The number of L and G units per macromer ranged 2.3-8.9 and 0.9-5.7, respectively.

3.2. Characterization of nanogels

Size distribution of P4, P8, and P12 NGs and their corresponding SEM images are shown in Figures 2a to 2c, respectively. Mean size, PD, and zeta potential of the NGs are given in Table 2. Mean size ranged from 120 ± 6 to 140 ± 13 nm for P4 NGs, 150 ± 11 to 160 ± 17 nm for P8 NGs, and 170 ± 12 to 190 ± 15 nm for P12 NGs. The NGs were relatively monodisperse with $PD < 0.2$ and the mean NG size increased with decreasing lactide fraction. All NGs had zeta potential between -23 and -15 mV. The absolute value of zeta potentials increased with increasing PEG molecular weight while the lactide fraction did not significantly affect zeta potential.

Table 2. Mean size, polydispersity (PD) and zeta potential of NGs based on PaLGb-Lc macromer. Error bars correspond to means $\pm$ 1 SD for $n=3$.

Group	NP type	Mean size(nm)	PD	Zeta potential (mv)
P4-I	P ₄ LG8-L75	118 ± 6	0.17 ± 0.04	-15.9 ± 1.9
P4-II	P ₄ LG8-L60	127 ± 10	0.15 ± 0.03	-15.3 ± 1.9
P4-III	P ₄ LG8-L50	140 ± 13	0.08 ± 0.01	-14.8 ± 1.3
P8-I	P ₈ LG16-L75	141 ± 11	0.15 ± 0.04	-18.6 ± 1.3
P8-II	P ₈ LG16-L60	158 ± 13	0.08 ± 0.01	-17.7 ± 1.7
P8-III	P ₈ LG16-L50	167 ± 17	0.07 ± 0.02	-18.5 ± 1.8
P12-I	P ₁₂ LG24-L75	165 ± 12	0.07 ± 0.01	-22.9 ± 1.7
P12-II	P ₁₂ LG24-L60	178 ± 15	0.10 ± 0.02	-22.3 ± 2.0
P12-III	P ₁₂ LG24-L50	190 ± 15	0.11 ± 0.01	-21.8 ± 1.5

The effect of concurrent (random, c) and sequential (block, s) addition of L and G monomers to the polymerization reaction on colloidal stability of the NGs was investigated (Supplementary Figure S2). NGs generated from P4-I macromers with concurrent addition of LG monomers (P4-Ic) had a significantly wider distribution ($PD=0.34\pm0.05$) than the sequential addition (0.17 ± 0.04 , Figures S2a and S2b). The mode of monomer addition did not significantly affect the mean size or zeta potential of the NGs (Figure S2a). P4-Is NGs were more stable in aqueous solution than P4-Ic NGs because their mean size did not change with incubation time (Figure S2c) and their precipitation from solution occurred over a narrower range of centrifugation speeds (Figure S2d). Therefore, the NGs with sequential polymerization of L and G monomers to PEG macromer were used for protein grafting.

Degradation of the NGs with incubation time was biphasic with an initial fast rate followed by a slow rate (Supplementary Figure S3). Degradation rate increased with decreasing L:G ratio

for all NGs. P12-I, P12-II and P12-III NGs degraded after 12, 16, and 18 days, respectively. P4-I NGs had the slowest degradation with $50 \pm 5\%$ mass loss after 30 days and P12-III NGs had the fastest degradation with $>95\%$ mass loss after 12 days. The release kinetics of BSA from the NGs in PBS was biphasic with a slightly faster initial rate (Figure 2d-f). The release of BSA increased with decreasing L:G ratio for all NGs. P4-I had the slowest BSA release with $45 \pm 8\%$ in 24 days and P12-III had the fastest with $>95\%$ released in 12 days.

Figure 2. Effect of PEG MW, LG segment length, and L/G ratio in PaLGB-Lc macromer on NG size distribution (a-c) and cumulative BSA release (d-f) in PBS with incubation time. (g) The release kinetics of BMP2 (blue circles) and VEGF (red circles) grafted to P8-I and P12-II NGs, respectively. Figure 2g also shows the release kinetics of BMP2 (blue squares) and VEGF (red squares) directly added to SPELA and GelMA gels, respectively, without NG grafting. The abbreviations P4, P8, and P12 in (a-f) represent NGs made from macromers with PEG MW=4, 8, and 12 kDa and average LG segment length of 8. The abbreviations P4-I, P4-II, and P4-III in (a-f) represent NGs with 4 kDa PEG MW with 75%, 60%, and 50% lactide in LG segments, respectively. Morphology of the dried NGs is shown in the inset SEM images in (a-c). Error bars correspond to means $\pm$ 1 SD for $n=3$.

3.3. Release kinetics of BMP2 and VEGF from nanogels

The extent of bone formation *in vivo* depends on duration of BMP2 exposure to MSCs in the first four weeks [7,8] whereas vascularization depends on VEGF exposure to endothelial progenitor cells within the first week [9]. The release kinetics of BMP2 (blue circles) and VEGF (red circles) grafted to P8-I and P12-II NGs, respectively, is shown in Figure 2g. Figure 2g also

shows the release kinetics of BMP2 (blue squares) and VEGF (red squares) directly added to SPELA and GelMA gels, respectively. The proteins directly added to the gels released in <40 h (inset of Figure 2g). VEGF grafted to P12-II NGs was released steadily in 10 days with ELISA-based bioactivity of $80\pm5\%$ whereas BMP2 grafted to P8-I NGs was released in 21 days with bioactivity of $71\pm3\%$. The grafting efficiency of BMP2 to P8-I NGs and VEGF to P12-II NGs was $96\pm1\%$ and $92\pm1\%$, respectively. The P12-II and P8-I NGs for grafting VEGF and/or BMP2 are hereafter referred to as NG(10) and NG(21), respectively.

3.4. Temporal effect of BMP2 and VEGF on osteogenic and vasculogenic differentiation of hMSCs and ECFCs in patterned constructs

Experimental groups included patterned constructs with NG(21)-BMP2/NG(10)-VEGF (blue) with 21 and 10 days release of BMP2 and VEGF, respectively; NG(10)-BMP2/NG(10)-VEGF (green) with 10 days release of BMP2 and VEGF; and NG(21)-BMP2/NG(21)-VEGF (red) with 21 days release of BMP2 and VEGF. DNA content, ALP activity, calcium content, and CD31 protein expression for ECFCs+hMSCs/NG-VEGF encapsulated in GelMA channels and hMSCs/NG-BMP2 encapsulated in SPELA matrix in the patterned constructs are shown in Figure 3. DNA content of the groups with BMP2/VEGF (with or without NG grafting) decreased with time which was related to the differentiation of encapsulated cells [36,50] (Figure 3a). The peak ALP and calcium content (at day 21) of NG(21)-BMP2/NG(10)-VEGF group was significantly higher than NG(10)-BMP2/NG(10)-VEGF but there was no significant difference between the peak ALP and calcium content of NG(21)-BMP2/NG(10)-VEGF and NG(21)-BMP2/NG(21)-VEGF groups. The protein expression of CD31 vasculogenic marker increased with time for all three groups (Figures 3d,e). CD31 expression of NG(21)-BMP2/NG(10)-VEGF group (0.91 ± 0.06) was significantly higher than NG(21)-BMP2/NG(21)-VEGF (0.70 ± 0.12) for all incubation times but there was no significant difference between the expressions of NG(21)-BMP2/NG(10)-VEGF and NG(10)-BMP2/NG(10)-VEGF groups. The differences in osteogenic and vasculogenic differentiation of hMSCs and ECFCs in Figure 3 can

be attributed to differences in duration of release (ten versus 21 days release) or the rate of growth factor release in the first 10 days. As the total amount of released proteins from NG(10) and NG(21) was the same, the release rate of BMP2/VEGF from NG(10) was faster than NG(21). The peak ALP activity at day 14 and calcium content at 21 of hMSCs in NG(21)-BMP2 groups (blue and red curves in Figures 3b,c) was significantly higher than those of NG(10)-BMP2 group (green curve) whereas there was insignificant difference between NG(10)-BMP2 and NG(21)-BMP2 groups at day 4. Conversely, CD31 expression of ECFCs in NG(10)-VEGF groups (blue and green curves in Figure 3d) was significantly higher than NG(21) group (red curve) for all time points ranging from 4 to 10 days (see also Figure 6d for bFGF). Therefore, the data suggest that the extent of osteogenic differentiation of hMSCs is related to the duration of BMP2 release whereas vasculogenic differentiation of ECFCs is related to the rate of release of VEGF. However, more data is needed to clearly discern the effect of release rate and duration of release on osteogenic and vasculogenic differentiation of hMSCs and ECFCs which will be investigated in future studies. Based on Figure 3 results, the patterned construct with 21 and 10 days release of BMP2 and VEGF, respectively, had highest expression of osteogenic and vasculogenic markers by the encapsulated hMSCs and ECFCs.

Figure 3. Temporal effect of BMP2 and VEGF on DNA content (a), ALP activity (b), calcium content (c), CD31 protein expression (d), representative western blot bands (e) for hMSCs and ECFCs in the patterned constructs. Groups included patterned constructs with NG(21)-BMP2/NG(10)-VEGF (blue), NG(21)-BMP2/NG(21)-VEGF (red) and NG(10)-BMP2/NG(10)-

VEGF (green). “One Asterisk” indicates statistically significant difference (s.d.; $p < 0.05$) between the test group and NG(10)-BMP2/NG(10)-VEGF (green); “two asterisks” indicates a significant difference between the test group and NG(21)-BMP2/NG(21)-VEGF (red). Error bars correspond to means ± 1 SD for $n=3$.

3.5. Osteogenic and vasculogenic differentiation of the encapsulated hMSCs and ECFCs in patterned constructs with timed-release of BMP2 and VEGF

DNA content, ALP activity, calcium content, and mRNA expression of osteogenic markers for ECFCs+hMSCs/NG-VEGF encapsulated in GelMA channels and hMSCs/NG-BMP2 encapsulated in SPELA matrix in the patterned constructs are shown in Figure 4 (blue curve). Controls included patterned constructs without BMP2/VEGF (green curve) and with direct addition of BMP2/VEGF, hMSCs/NG-BMP2 (dashed light blue) and hMSCs/BMP2 (dashed pink) in unpatterned osteogenic constructs. DNA content of the groups with BMP2/VEGF (with or without NG grafting) decreased with time which was related to the differentiation of encapsulated cells [36,50] (Figure 4a). ALP activity of hMSCs in the unpatterned osteogenic constructs with BMP2 or NG-BMP2 (dashed curves) increased significantly from day 7 to 14, reached a maximum after 14 days and decreased from day 14 to 21 (Figure 4b). The peak ALP activity of hMSCs in the patterned constructs with BMP2/VEGF (with or without grafting) was delayed to day 18 because the constructs were cultured in vasculogenic medium in the first 7 days (Figure 4b). The patterned constructs (solid lines) had higher ALP activity than their corresponding unpatterned osteogenic constructs (dashed lines). The patterned constructs with NG-BMP2/NG-VEGF (blue curve) and without BMP2/VEGF (green curve) had the highest and lowest ALP activity with 6100 ± 500 and 2000 ± 300 IU/mg DNA, respectively. Calcium content as a measure of the extent of mineralization for all groups steadily increased with incubation time (Figure 4c). After 21 days incubation, the patterned constructs (solid lines) had higher calcium content than their corresponding unpatterned osteogenic constructs (dashed lines). The patterned constructs with NG-BMP2/NG-VEGF (blue curve) and without BMP2/VEGF (green curve) had the highest and lowest calcium content after 21 days with 710 ± 50 and 220 ± 30 mg/mg DNA, respectively (Figure 4c).

The mRNA expression of Runx2 transcription factor initially increased with incubation time for all groups, peaked at day 14, and then decreased (Figure 4d). The unpatterned osteogenic construct with NG-BMP2 and the patterned construct with NG-BMP2/NG-VEGF had the highest Runx2 expression while the patterned construct without BMP2/VEGF had the lowest expression (Figure 4d). mRNA expression of ALP (Figure 4e) followed a trend similar to that of ALP activity shown in Figure 4b. The patterned construct with NG-BMP2/NG-VEGF (blue curve) had highest ALP expression at day 14. mRNA expression for Col I for all groups increased steadily with incubation time (Figure 4f). The unpatterned osteogenic construct with NG-BMP2 and the patterned construct with NG-BMP2/NG-VEGF had highest Col I expression after 21 days. The images in Figure 4g show Alizarin red staining along the length of a microchannel for the patterned constructs with None, directly added, and NG-BMP2/NG-VEGF after 4 and 21 days of incubation. The image for patterned construct with NG-BMP2/NG-VEGF after 21 days (bottom right image) showed a greater difference in staining intensity between the osteogenic matrix (dark-red) and vasculogenic microchannel (red) as compared to other groups.

Figure 4. DNA content (a), ALP activity (b), calcium content (c), and mRNA expression of osteogenic markers Runx2 (d), ALP (e), and Col I (f) for hMSCs and ECFCs encapsulated in the patterned constructs. Groups included patterned constructs without VEGF/BMP2 (green), with VEGF/BMP2 (red), and with NG-VEGF/NG-BMP2 (blue); unpatterned osteogenic constructs with NG-BMP2 (dashed light blue) and BMP2 (dashed pink). Patterned constructs were incubated in vasculogenic medium for 7 days, vasculogenic/osteogenic medium for 3 days, and

osteogenic medium for 11 days (without VEGF, BMP2, or DEX). Unpatterned constructs were incubated in osteogenic medium without DEX or BMP2 for 21 days. (g) Alizarin red stained (dark red) images of the patterned constructs along the length of a microchannel with None, directly added, and NG-grafted BMP2/VEGF after 4 and 21 days of incubation. “An asterisk” represents a statistically significant difference between the test and None groups for the same time point; “Two asterisks” represents a significant difference between the test group and patterned construct with VEGF/BMP2. Error bars correspond to means $\pm$ 1 SD for n=3.

DNA content, CD31 protein, and mRNA expression of vasculogenic markers for ECFCs+hMSCs/NG-VEGF encapsulated in GelMA channels and hMSCs/NG-BMP2 encapsulated in SPELA matrix in the patterned constructs are shown in Figure 5 (blue curve). Controls included patterned constructs without BMP2/VEGF (green curve) and with direct addition of BMP2/VEGF, unpatterned vasculogenic constructs hMSCs+ECFCs/NG-VEGF (dashed light blue) and hMSCs+ECFCs/VEGF (dashed pink) in GelMA. CD31 protein expression for the patterned construct without BMP2/VEGF (green curve) did not increase significantly with time (Figure 5b,c). CD31 expression of the unpatterned vasculogenic constructs with VEGF (dashed pink) or NG-VEGF (dashed light blue) increased with time but the expression for NG-VEGF was significantly higher than that of VEGF (Figure 5b,c). The patterned constructs (solid lines) had higher CD31 expression than the unpatterned constructs (dashed lines) for all incubation times. For example after 10 days, CD31 expressions for patterned constructs with NG-BMP2/NG-VEGF and BMP2/VEGF were 0.91 ± 0.08 and 0.75 ± 0.12 , respectively; the expressions for the unpatterned constructs were 0.78 ± 0.12 and 0.52 ± 0.07 . For all time points, CD31 expression of patterned construct with NG-BMP2/NG-VEGF was higher than the other groups. mRNA expressions of vWF, CD31, and VE-cadherin (Figure 5d-f) with incubation time were consistent with the CD31 protein expressions in Figure 5b. The images in Figure 5g show CD31 staining (green) along the length of a microchannel for the patterned constructs with None, directly added, and NG-BMP2/NG-VEGF after 4 and 10 days of incubation. The image for patterned construct with NG-BMP2/NG-VEGF after 21 days (bottom right image) showed a greater difference in CD31 staining intensity between the osteogenic matrix (dark/blue) and vasculogenic microchannel (dark/green) as compared to other groups.

Figure 5. DNA content (a), CD31 protein expression (b), representative western blot bands (c), and mRNA expression of vasculogenic markers vWF (d), CD31 (e), and VE-cadherin (f) for hMSCs and ECFCs encapsulated in the patterned constructs. Groups included patterned constructs without VEGF/BMP2 (green), with VEGF/BMP2 (red), and with NG-VEGF/NG-BMP2 (blue); unpatterned vasculogenic constructs with NG-VEGF (dashed light blue) and VEGF (dashed pink). (g) CD31 stained (green) images of the patterned constructs along the length of a microchannel with None, directly added, and NG-grafted BMP2/VEGF after 4 and 10 days of incubation. “An asterisk” represents a statistically significant difference in the ordinate between the test and None groups for the same time point; “Two asterisks” represents a significant difference between the test group and the patterned construct with VEGF/BMP2. Error bars correspond to means $\pm$ 1 SD for n=3.

The bFGF protein expression of the unpatterned osteogenic, unpatterned vasculogenic, and patterned constructs are shown in Figures 6a-c, respectively. Figure 6d shows the temporal effect of VEGF and BMP2 in patterned constructs on bFGF protein expression.

Figure 6. bFGF protein expression of the unpatterned osteogenic (a) and vasculogenic (b), and patterned (c) constructs with incubation time. Groups included patterned constructs without

(green, c) and with VEGF/BMP2 (red, c), and with NG(21)-BMP2/NG(10)-VEGF (blue, c); unpatterned osteogenic constructs with NG(21)-BMP2 (dashed light blue, a) and BMP2 (dashed pink, a); and unpatterned vasculogenic constructs with NG(10)-VEGF (dashed light blue, b) and VEGF (dashed pink, b). Figure d is the temporal effect of BMP2 and VEGF on bFGF protein expression in the patterned constructs. Groups in d included NG(21)-BMP2/NG(10)-VEGF (dashed blue), NG(21)-BMP2/NG(21)-VEGF (dashed red), and NG(10)-BMP2/NG(10)-VEGF (dashed green). “An asterisk” represents statistically significant difference (s.d.; $p < 0.05$) between the test group and None (green); “Two asterisks” represents a significant difference between the test group and BMP2 (pink in a) or VEGF (dashed pink in b) or BMP2/VEGF (red in c) or NG(21)-BMP2/NG(21)-VEGF (dashed red in d). Error bars correspond to means $\pm$ 1 SD for $n=3$.

For a given time point, patterned constructs and unpatterned osteogenic constructs, with or without protein grafting, had highest and lowest expression of bFGF, respectively. Overall, the patterned construct with NG-BMP2/NG-VEGF had highest expression of bFGF after 14 and 21 days among all groups (Figure 6c). For example, bFGF expression of the patterned constructs with None, directly added, and NG(21)-BMP2/NG(10)-VEGF after 21 days incubation were 160 ± 7 , 54 ± 4 , and 23 ± 1 ng/mL, respectively (Figure 6c); unpatterned vasculogenic constructs with None, directly added, and NG(10)-VEGF were 110 ± 12 , 48 ± 4 , and 19 ± 5 ng/mL (Figure 6b); and unpatterned osteogenic constructs with None, directly added, and NG(21)-BMP2 were 49 ± 7 , 14 ± 4 , and zero ng/mL (Figure 6a). With regard to the temporal effect of BMP2 and VEGF, the patterned constructs with NG(21)-BMP2/NG(10)-VEGF and NG(10)-BMP2/NG(10)-VEGF had similar bFGF expressions which were higher than NG(21)-BMP2/NG(21)-VEGF.

4. Discussion

Size distribution of NPs self-assembled from PEG-LG macromers is dependent on the length of LG segment [51]. NPs generated previously by us from ultra-low molecular weight ULMW-PLGA (1-2 kDa MW) with amphiphilic copolymers of PEG (3.4 kDa) and ULMW-PLA (PLEOF) had L segment length of 15-30, mean size of 250 nm, and size distribution of 100 to 600 nm [10]. The approach used in this work to generate NGs by sequential extension of PEG chain-ends with short L and G segments resulted in lower L segment length and mean NG size, and narrower size distribution (Table 1). The PEG block in PaLGB-Lc NGs regulated the extent of association between the macromers by balancing van der Waals, polar, and hydrogen-bonding

interactions to prevent aggregation of LG segments [52]. The measured zeta potentials of the NGs (-15 to -22 mv) was less than the reported values for PLGA NPs (-50 mv) [53] which was attributed to the lower fraction of carboxyl groups in the NGs' corona [52]. The degradation kinetics of PEG-LG based NGs depends on the proximity of water molecules to L and G ester groups [54], which is dependent on PEG MW and the length of L and G segments [55]. Consequently, PEG MW had the greatest effect on NGs degradation followed by the fraction of less hydrophobic G segments (Supplementary Figure S3). VEGF and BMP2 proteins were released from the NGs at a constant rate for 10 and 21 days, respectively, without an initial burst release, with $80\pm5\%$ and $71\pm3\%$ release of bioactive proteins [11] (Figure 2g). PLGA and heparin-functionalized PLGA NPs and gelatin microparticles have previously been used for BMP2 and VEGF delivery, respectively [11,28]. Immobilization of BMP2 on heparin-functionalized PLGA (90 kDa) NPs and encapsulation in a fibrin gel prolonged protein release to 2 weeks, but the fraction of biologically active BMP2 released was 23% compared to 57% for untreated NPs [28]. Encapsulation of VEGF in gelatin microparticles prolonged release to 2 weeks but <45% of the protein was released from the particles [11]. In another study, copolymerization of PLGA with PEG (5 kDa) increased the fraction of BSA released from the NPs from 50% to 70% after 1 week of incubation [13].

Several recent studies have investigated the combined effect of VEGF and BMP2 on osteogenesis and vascularization [19,20,22-24]. Based on previous experimental results, co-expression of BMP2 and VEGF in MSC cultures had no effect on the extent of mineralization *in vitro*. On the other hand, combination of MSCs and EPCs in a calcium sulfate scaffold without over-expression of BMP2 showed higher mineralization *in vitro* compared to the group with only BMP2-expressing MSC [20]. Dual delivery of VEGF and BMP2 *in vivo* increased bone formation only at early time points but it was relatively independent of VEGF at late time points [22,24,25]. In another study, co-culture of BMP2-expressing MSCs and VEGF-expressing EPCs in a scaffold significantly increased bone formation after intramuscular implantation in rat [23]. The previous results indicate that dual delivery of BMP2 and VEGF increases osteogenesis only

when MSCs are co-cultured with EPCs. Our results in Figures 4 and 5 demonstrate that localized, dual delivery of VEGF to ECFCs+hMSCs in the channels and BMP2 to hMSCs in the matrix significantly increased the extent of mineralization and vascularization. Further, timed-release of VEGF and BMP2 by grafting to NG(10) and NG(21), respectively, in the channels and matrix significantly improved mineralization and vascularization (blue curves in Figures 4-5) compared to direct addition of VEGF/BMP2 (red curves in Figures 4-5). The ELISA data in Figure 2g and the cell culture data in Figures 4-5 confirm the biological activity of the released VEGF and BMP2 from the NGs with respect to vasculogenic and osteogenic differentiation of ECFCs and hMSCs, respectively.

These results suggest that differentiation and maturation of MSCs and ECFCs to osteoblasts and endothelial cells induced by BMP2 and VEGF, respectively, may be indirectly coupled; that is, differentiation of ECFCs in the channels by VEGF releases osteogenic factors that diffuse to the matrix and stimulate osteogenesis. bFGF is known to mediate vascularization and bone formation in scaffolds seeded with MSCs [56,57]. Therefore, the expression of bFGF at the protein level for the unpatterned and patterned constructs was measured (Figure 6). The unpatterned vasculogenic and osteogenic constructs without VEGF and BMP2, respectively, expressed low levels of bFGF (green in b) or no bFGF (green in a). The unpatterned vasculogenic constructs with VEGF (dashed pink and blue in b) had higher expression of bFGF than the unpatterned osteogenic constructs with BMP2 (dashed pink and blue in a). bFGF expression of the patterned construct with direct addition of BMP2/VEGF (red in c) was comparable to those of the unpatterned vasculogenic construct with VEGF (dashed pink in b). Overall, timed-release of BMP2/VEGF from NGs significantly enhanced bFGF expression level in the unpatterned (dashed pink in a,b) and patterned (blue in c) constructs compared to direct addition of proteins. However, timed-release of BMP2/VEGF in the patterned construct sharply increased bFGF expression level after 14 and 21 days (blue in c) compared to direct addition of VEGF/BMP2 (red in c). The data in Figure 6 shows that the temporal release of BMP2 in 21 days from NG(21) significantly increased bFGF expression in the patterned constructs. The results

with NG-BMP2/NG-VEGF are consistent with previous reports on the effect of timed-release of VEGF and BMP2 on vascularization and osteogenesis, respectively [58,59].

The data in Figure 6 suggest that the differentiated ECFCs+hMSCs in the channels secrete bFGF, and possibly other growth factors, that synergistically enhance osteogenic differentiation of hMSCs and mineralization. The data also indicates that timed-release of NG-grafted VEGF in the channels leads to sustained secretion of bFGF in the first week of co-culture to stimulate maturation of the differentiated cells to osteoblasts and endothelial cells. In clinical applications, MSCs and ECFCs can be harvested from the patient's bone marrow and peripheral blood, respectively. MSCs and NG-BMP2 are encapsulated in the matrix, MSCs+ECFCs and NG-VEGF are encapsulated in the channels. The cellular patterned hydrogel is inserted inside a rigid, cortical-bone-like shell, implanted in a large bone defect, and stabilized using an internal plate with locking screws. The localized secretion of paracrine signaling factors (i.e., bFGF) by the differentiating MSCs and ECFCs accelerates regeneration and bone healing.

5. Conclusion

This work investigated the effect of spatial and temporal release of BMP2 and VEGF on the coupling of osteogenesis and vascularization in a patterned construct with hMSCs encapsulated in the matrix and hMSCs+ECFCs encapsulated in the microchannels. For timed-release, BMP2 and VEGF were grafted to resorbable NGs based on PEG macromers chain-extended with a short L segment for self-assembly and a short G segment for degradation. The release kinetics of proteins from the NGs could be tuned to the desired rate by changing PEG MW and L to G ratio. Timed-release of VEGF in the microchannels in 10 days from NG(10) and BMP2 in the matrix in 21 days from NG(21) significantly increased osteogenic and vasculogenic differentiation of hMSCs and ECFCs compared to direct addition of VEGF and BMP2. Timed-release of VEGF from NG(10) in the microchannels and BMP2 from NG(21) in the matrix resulted in highest extent of osteogenic and vasculogenic differentiation of the encapsulated hMSCs and ECFCs and sharply increased bFGF expression in the patterned constructs. The

results suggest that mineralization and vascularization may be coupled by localized secretion of paracrine signaling factors like bFGF by the differentiating hMSCs and ECFCs.

Acknowledgements

This work was supported by research grants to E. Jabbari from the United States National Science Foundation under Award Numbers CBET1403545 and IIP150024 and the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Number AR063745. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

References

- [1] C.S. Molina, D.J. Stinner, W.T. Obrebsky, Treatment of traumatic segmental long-bone defects: A critical analysis review, *JBJS Rev.* 2 (2014) e1.
- [2] H. Yasuda, K. Yano, S. Wakitani, T. Matsumoto, H. Nakamura, K. Takaoka, Repair of critical long bone defects using frozen bone allografts coated with an rhBMP-2-retaining paste, *J. Orthop. Sci.* 17 (2012) 299-307.
- [3] S.N. Lissenberg-Thunnissen, D.J.J. de Gorter, C.F.M. Sier, I.B. Schipper, Use and efficacy of bone morphogenetic proteins in fracture healing, *Int. Orthop.* 35 (2011) 1271-1280.
- [4] E.J. Carragee, E.L. Hurwitz, B.K. Weiner, A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: Emerging safety concerns and lessons learned, *Spine J.* 11 (2011) 471-491.
- [5] Y.Q. Yang, Y.Y. Tan, R. Wong, A. Wenden, L.K. Zhang, A.B.M. Rabie, The role of vascular endothelial growth factor in ossification, *Int. J. Oral Sci.* 4 (2012) 64-68.
- [6] J. Street, M. Bao, S. Bunting, F.V. Peale, N. Ferrara, H. Steinmetz, J. Hoeffel, J.L. Cleland, A. Daugherty, N. van Bruggen, Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover, *Proc. Natl. Acad. Sci.* 99 (2002) 9656-9661.
- [7] J.C. Park, J.C. Kim, B.K. Kim, K.S. Cho, G.I. Im, B.S. Kim, C.S. Kim, Dose- and time-dependent effects of recombinant human bone morphogenetic protein-2 on the osteogenic and adipogenic potentials of alveolar bone-derived stromal cells, *J. Periodontal Res.* 47 (2012) 645-54.
- [8] O. Jeon, S.J. Song, H.S. Yang, S.-H. Bhang, S.-W. Kang, M. Sung, J.H. Lee, B.-S. Kim, Long-term delivery enhances in vivo osteogenic efficacy of bone morphogenetic protein-2 compared to short-term delivery, *Biochem. Biophys. Res. Commun.* 369 (2008) 774-780.
- [9] Y.C. Chen, R.Z. Lin, H. Qi, Y.Z. Yang, H.J. Bae, J.M. Melero-Martin, A. Khademhosseini, Functional human vascular network generated in photocrosslinkable gelatin methacrylate hydrogels, *Adv. Funct. Mater.* 22 (2012) 2027-2039.

- [10] A.E. Mercado, J.Y. Ma, X.Z. He, E. Jabbari, Release characteristics and osteogenic activity of recombinant human bone morphogenetic protein-2 grafted to novel self-assembled poly(lactide-co-glycolide fumarate) nanoparticles, *J. Contr. Rel.* 140 (2009) 148-156.
- [11] M.T. Poldervaart, H. Gremmels, K. van Deventer, J.O. Fledderus, F.C. Oner, M.C. Verhaar, W.J.A. Dhert, J. Alblas, Prolonged presence of VEGF promotes vascularization in 3D bioprinted scaffolds with defined architecture, *J. Contr. Rel.* 184 (2014) 58-66.
- [12] J. Kleinheinz, S. Jung, K. Wermker, C. Fischer, U. Joos, Release kinetics of VEGF165 from a collagen matrix and structural matrix changes in a circulation model, *Head Face Med.* 6 (2010) 17.
- [13] Y.-P. Li, Y.-Y. Pei, X.-Y. Zhang, Z.-H. Gu, Z.-H. Zhou, W.-F. Yuan, J.-J. Zhou, J.-H. Zhu, X.-J. Gao, Pegylated PLGA nanoparticles as protein carriers: Synthesis, preparation and biodistribution in rats, *J. Contr. Rel.* 71 (2001) 203-211.
- [14] S.E. Bae, J. Choi, Y.K. Joung, K. Park, D.K. Han, Controlled release of bone morphogenetic protein (bmp)-2 from nanocomplex incorporated on hydroxyapatite-formed titanium surface, *J. Contr. Rel.* 160 (2012) 676-684.
- [15] J.P. Levesque, F.M. Helwani, I.G. Winkler, The endosteal 'osteoblastic' niche and its role in hematopoietic stem cell homing and mobilization, *Leukemia* 24 (2010) 1979-1992.
- [16] J. Dai, A.B.M. Rabie, VEGF: An essential mediator of both angiogenesis and endochondral ossification, *J. Dental Res.* 86 (2007) 937-950.
- [17] A.B.M. Rabie, U. Hagg, Factors regulating mandibular condylar growth, *Am. J. Orthod. Dentofacial Orthop.* 122 (2002) 401-409.
- [18] H.G. Kopp, A.T. Hooper, S.T. Avecilla, S. Rafii, Functional heterogeneity of the bone marrow vascular niche, *Hematopoietic Stem Cells VII* 1176 (2009) 47-54.
- [19] Z.W. Lin, J.S. Wang, L.J. Lin, J.W. Zhang, Y.L. Liu, M. Shuai, Q. Li, Effects of BMP2 and VEGF165 on the osteogenic differentiation of rat bone marrow-derived mesenchymal stem cells, *Exp. Therapeut. Med.* 7 (2014) 625-629.
- [20] X.N. He, R. Dziak, X. Yuan, K.Y. Mao, R. Genco, M. Swihart, D. Sarkar, C.Y. Li, C.D. Wang, L. Lu, S. Andreadis, S.Y. Yang, BMP2 genetically engineered MSCs and EPCs promote vascularized bone regeneration in rat critical-sized calvarial bone defects, *PloS One* 8 (2013) e60473.
- [21] R.Z. Lin, R. Moreno-Luna, D. Li, S.C. Jaminet, A.K. Greene, J.M. Melero-Martin, Human endothelial colony-forming cells serve as trophic mediators for mesenchymal stem cell engraftment via paracrine signaling, *Proc. Natl. Acad. Sci. U.S.A.* 111 (2014) 10137-10142.
- [22] R.E. Geuze, L.F.H. Theyse, D.H.R. Kempen, H.A.W. Hazewinkel, H.Y.A. Kraak, F.C. Oner, W.J.A. Dhert, J. Alblas, A differential effect of bone morphogenetic protein-2 and vascular endothelial growth factor release timing on osteogenesis at ectopic and orthotopic sites in a large-animal model, *Tissue Eng. Part A* 18 (2012) 2052-2062.
- [23] X.B. Song, S.H. Liu, X. Qu, Y.W. Hu, X.Y. Zhang, T. Wang, F.C. Wei, BMP2 and VEGF promote angiogenesis but retard terminal differentiation of osteoblasts in bone regeneration by up-regulating id1, *Acta Biochim. Biophys. Sin.* 43 (2011) 796-804.
- [24] Z.S. Patel, S. Young, Y. Tabata, J.A. Jansen, M.E.K. Wong, A.G. Mikos, Dual delivery of an angiogenic and an osteogenic growth factor for bone regeneration in a critical size defect model, *Bone* 43 (2008) 931-940.

- [25] D.H.R. Kempen, L.C. Lu, A. Heijink, T.E. Hefferan, L.B. Creemers, A. Maran, M.J. Yaszemski, W.J.A. Dhert, Effect of local sequential VEGF and BMP-2 delivery on ectopic and orthotopic bone regeneration, *Biomaterials* 30 (2009) 2816-2825.
- [26] H. Matsubara, D.E. Hogan, E.F. Morgan, D.P. Mortlock, T.A. Einhorn, L.C. Gerstenfeld, Vascular tissues are a primary source of BMP2 expression during bone formation induced by distraction osteogenesis, *Bone* 51 (2012) 168-180.
- [27] A.E. Mercado, X. He, W. Xu, E. Jabbari, The release characteristics of a model protein from self-assembled succinimide-terminated poly (lactide-co-glycolide ethylene oxide fumarate) nanoparticles, *Nanotechnology* 19 (2008) 325609.
- [28] Y.-I. Chung, K.-M. Ahn, S.-H. Jeon, S.-Y. Lee, J.-H. Lee, G. Tae, Enhanced bone regeneration with BMP-2 loaded functional nanoparticle-hydrogel complex, *J. Contr. Rel.* 121 (2007) 91-99.
- [29] G. Zhu, S.R. Mallery, S.P. Schwendeman, Stabilization of proteins encapsulated in injectable poly (lactide-co-glycolide), *Nature biotechnol.* 18 (2000) 52-57.
- [30] G. Crotts, H. Sah, T.G. Park, Adsorption determines in-vitro protein release rate from biodegradable microspheres: Quantitative analysis of surface area during degradation, *J. Contr. Rel.* 47 (1997) 101-111.
- [31] S. Zhang, C. Kucharski, M.R. Doschak, W. Sebald, H. Uludag, Polyethylenimine PEG coated albumin nanoparticles for BMP-2 delivery, *Biomaterials* 31 (2009) 952-963.
- [32] T. Simon-Yarza, F.R. Formiga, E. Tamayo, B. Pelacho, F. Prosper, M.J. Blanco-Prieto, Pegylated-PLGA microparticles containing VEGF for long term drug delivery, *Int. J. Pharmaceut.* 440 (2013) 13-18.
- [33] S. Koutsopoulos, L.D. Unsworth, Y. Nagai, S.G. Zhang, Controlled release of functional proteins through designer self-assembling peptide nanofiber hydrogel scaffold, *Proc. Natl. Acad. Sci. U.S.A.* 106 (2009) 4623-4628.
- [34] M.E. Davis, P.C.H. Hsieh, T. Takahashi, Q. Song, S.G. Zhang, R.D. Kamm, A.J. Grodzinsky, P. Anversa, R.T. Lee, Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction, *Proc. Natl. Acad. Sci. U.S.A.* 103 (2006) 8155-8160.
- [35] S. Moeinzadeh, D. Barati, S.K. Sarvestani, O. Karaman, E. Jabbari, Nanostructure formation and transition from surface to bulk degradation in polyethylene glycol gels chain-extended with short hydroxy acid segments, *Biomacromolecules* 14 (2013) 2917-2928.
- [36] S. Moeinzadeh, D. Barati, X. He, E. Jabbari, Gelation characteristics and osteogenic differentiation of stromal cells in inert hydrolytically degradable micellar polyethylene glycol hydrogels, *Biomacromolecules* 13 (2012) 2073-2086.
- [37] X. He, X. Yang, E. Jabbari, Combined effect of osteopontin and BMP-2 derived peptides grafted to an adhesive hydrogel on osteogenic and vasculogenic differentiation of marrow stromal cells, *Langmuir* 28 (2012) 5387-97.
- [38] A.I. Van Den Bulcke, B. Bogdanov, N. De Rooze, E.H. Schacht, M. Cornelissen, H. Berghmans, Structural and rheological properties of methacrylamide modified gelatin hydrogels, *Biomacromolecules* 1 (2000) 31-38.

- [39] A.E. Mercado, E. Jabbari, Effect of encapsulation or grafting on release kinetics of recombinant human bone morphogenetic protein-2 from self-assembled poly (lactide-co-glycolide ethylene oxide fumarate) nanoparticles, *Micros. Res. Tech.* 73 (2010) 824-833.
- [40] X. He, E. Jabbari, Material properties and cytocompatibility of injectable MMP degradable poly(lactide ethylene oxide fumarate) hydrogel as a carrier for marrow stromal cells, *Biomacromolecules* 8 (2007) 780-792.
- [41] S. Moeinzadeh, D. Barati, S.K. Sarvestani, T. Karimi, E. Jabbari, Experimental and computational investigation of the effect of hydrophobicity on aggregation and osteoinductive potential of BMP-2-derived peptide in a hydrogel matrix, *Tissue Eng. Part A* 21 (2015) 134-146.
- [42] J.M. Melero-Martin, Z.A. Khan, A. Picard, X. Wu, S. Paruchuri, J. Bischoff, In vivo vasculogenic potential of human blood-derived endothelial progenitor cells, *Blood* 109 (2007) 4761-4768.
- [43] D. Barati, S. Moeinzadeh, O. Karaman, E. Jabbari, Time dependence of material properties of polyethylene glycol hydrogels chain extended with short hydroxy acid segments, *Polymer* 55 (2014) 3894-3904.
- [44] J.A. Henderson, X. He, E. Jabbari, Concurrent differentiation of marrow stromal cells to osteogenic and vasculogenic lineages, *Macromol. Biosci.* 8 (2008) 499-507.
- [45] B. Orlando, L. Giacomelli, M. Ricci, A. Barone, U. Covani, Leader genes in osteogenesis: A theoretical study, *Arch. Oral Biol.* 58 (2013) 42-49.
- [46] X. Chen, N. Li, LeleYang, J.L. Liu, J.H. Chen, H.T. Liu, Expression of collagen I, collagen III and MMP-1 on the tension side of distracted tooth using periodontal ligament distraction osteogenesis in beagle dogs, *Arch. Oral Biol.* 59 (2014) 1217-1225.
- [47] E.E. Golub, K. Boesze-Battaglia, The role of alkaline phosphatase in mineralization, *Curr. Opin. Orthop.* 18 (2007) 444-448.
- [48] B.P. Herring, A.M. Hoggatt, C. Burlak, S. Offermanns, Von willebrand factor regulates angiogenesis and VEGFR2 signalling: Implications for angiodysplasia and vascular malformations in von willebrand disease, *Angiogenesis* 17 (2014) 969-969.
- [49] C. Tepekoylu, F.S. Wang, R. Kozaryn, K. Albrecht-Schgoer, M. Theurl, W. Schaden, H.J. Ke, Y.J. Yang, R. Kirchmair, M. Grimm, C.J. Wang, J. Holfeld, Shock wave treatment induces angiogenesis and mobilizes endogenous CD31/CD34-positive endothelial cells in a hindlimb ischemia model: Implications for angiogenesis and vasculogenesis, *J. Thoracic Cardiovasc. Surg.* 146 (2013) 971-978.
- [50] J.A. Burdick, K.S. Anseth, Photoencapsulation of osteoblasts in injectable RGD-modified PEG hydrogels for bone tissue engineering, *Biomaterials* 23 (2002) 4315-4323.
- [51] S. Forster, M. Zisenis, E. Wenz, M. Antonietti, Micellization of strongly segregated block copolymers, *J. Chem. Phys.* 104 (1996) 9956-9970.
- [52] J.V. Jokerst, T. Lobovkina, R.N. Zare, S.S. Gambhir, Nanoparticle pegylation for imaging and therapy, *Nanomedicine* 6 (2011) 715-728.
- [53] A. Beletsi, Z. Panagi, K. Avgoustakis, Biodistribution properties of nanoparticles based on mixtures of PLGA with PLGA-PEG diblock copolymers, *Int. J. Pharmaceut.* 298 (2005) 233-241.

- [54] M.L.T. Zweers, G.H.M. Engbers, D.W. Grijpma, J. Feijen, In vitro degradation of nanoparticles prepared from polymers based on dl-lactide, glycolide and poly (ethylene oxide), *J. Contr. Rel.* 100 (2004) 347-356.
- [55] K. Avgoustakis, A. Beletsi, Z. Panagi, P. Klepetsanis, A.G. Karydas, D.S. Ithakissios, PLGA-mPEG nanoparticles of cisplatin: In vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties, *J. Contr. Rel.* 79 (2002) 123-135.
- [56] J.M. Kim, H.I. Shin, S.S. Cha, C.S. Lee, B.S. Hong, S. Lim, H.J. Jang, J. Kim, Y.R. Yang, Y.H. Kim, S. Yun, G. Rijal, W. Lee-Kwon, J.K. Seo, Y.S. Gho, S.H. Ryu, E.M. Hur, P.G. Suh, Dj-1 promotes angiogenesis and osteogenesis by activating FGF receptor-1 signaling, *Nature Commun.* 3 (2012) 1296.
- [57] D. Qu, J.H. Li, Y.B. Li, Y. Gao, Y. Zuo, Y.C. Hsu, J. Hu, Angiogenesis and osteogenesis enhanced by bFGF ex vivo gene therapy for bone tissue engineering in reconstruction of calvarial defects, *J. Biomed. Mater. Res. Part A* 96 (2011) 543-551.
- [58] F.R. Formiga, B. Pelacho, E. Garbayo, G. Abizanda, J.J. Gavira, T. Simon-Yarza, M. Mazo, E. Tamayo, C. Jauquicoa, C. Ortiz-de-Solorzano, Sustained release of VEGF through PLGA microparticles improves vasculogenesis and tissue remodeling in an acute myocardial ischemia-reperfusion model, *J. Contr. Rel.* 147 (2010) 30-37.
- [59] A. des Rieux, B. Ucakar, B.P.K. Mupendwa, D. Colau, O. Feron, P. Carmeliet, V. Preat, 3D systems delivering VEGF to promote angiogenesis for tissue engineering, *J. Contr. Rel.* 150 (2011) 272-278.

Differentiation of hMSCs+ECFCs in the microchannels and hMSCs in the matrix by timed-release of VEGF and BMP2, respectively, in a patterned hydrogel construct leads to localized secretion of paracrine signaling factors and coupling of mineralization and vascularization.